Ono Pharmaceutical Signs an Exclusive License Agreement with Forty Seven to Develop and Commercialize 5F9 in Selected Asian Countries
Shots:
- Forty Seven to receive ~ $15.8M up front- ~$104M as development and commercial milestones and royalties on sales of 5F9 in selected territories and will retain WW rights of 5F9 including the US- EU and China
- Ono to get exclusive rights to develop and commercialize 5F9 as monothx./combination therapy for all therapeutic uses in Japan- South Korea- Taiwan and selected Southeast Asian countries and will participate in global clinical studies of 5F9 in selected territories
- 5F9 is mAb targeting CD47 and has received FDA’s FT designation for r/r DLBCL- FL- two forms of B-cell NHL and FDA & EMA’s ODD for AML
Click here to read full press release/ article | Ref: Globe NewsWire | Image: Forty Seven
Tags
Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at [email protected]
